ImmunoGen

$8.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.73 (+10.12%) Today

+$0.14 (+1.76%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ImmunoGen and other stocks, options, and ETFs commission-free!

About IMGN

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA. The listed name for IMGN is ImmunoGen, Inc. Common Stock.

CEO

Mark J. Enyedy

Employees

Headquarters

Waltham, Massachusetts

Founded

1981

Market Cap

1.51B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

2.61M

High Today

$8.10

Low Today

$7.24

Open Price

$7.34

Volume

3.28M

52 Week High

$8.10

52 Week Low

$1.95

Collections

Analyst Ratings

56%

of 9 ratings

Buy

56%

Hold

44%

Sell

IMGN Earnings

-$0.33

-$0.21

-$0.09

$0.03

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 12, Pre-Market